
Haemonetics Corporation: updates and filings
Price
$121.98
November 19, 2026Market cap $5.5B
What Ploutos Investor adds for Haemonetics
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
February 2026
January 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 5, 2026Quarterly reportfor the period to Sep 26, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Oct 8, 2026Regulation FD disclosureForm8-K
- Aug 18, 2026Regulation FD disclosureForm8-K
- Aug 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 6, 2026Shares registered for employeesFormS-8
- Aug 6, 2026Quarterly reportfor the period to Jun 27, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jul 28, 2026Officer or director change, shareholder voteForm8-K
- Jun 9, 2026Annual report to shareholdersfor the period to Mar 28, 2026FormARS
- Jun 9, 2026Additional annual meeting materialFormDEFA14A
- Jun 9, 2026Annual meeting proxy statementFormDEF 14A
- Jun 5, 2026Regulation FD disclosureForm8-K
- May 28, 2026Conflict minerals reportFormSD
- May 20, 2026Annual reportfor the period to Mar 28, 2026Form10-K
- May 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 7, 2026Results of operationsForm8-K
- May 1, 2026Officer or director changeForm8-K
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 3, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Mar 3, 2026Regulation FD disclosureForm8-K
- Feb 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Feb 12, 2026Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 26, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Oct 8, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 18, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 6, 2026 | S-8 | Shares registered for employees | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 27, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jul 28, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| Jun 9, 2026 | ARS | Annual report to shareholdersfor the period to Mar 28, 2026 | Document |
| Jun 9, 2026 | DEFA14A | Additional annual meeting material | Document |
| Jun 9, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Jun 5, 2026 | 8-K | Regulation FD disclosure | Document |
| May 28, 2026 | SD | Conflict minerals report | Document |
| May 20, 2026 | 10-K | Annual reportfor the period to Mar 28, 2026 | Document |
| May 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| May 1, 2026 | 8-K | Officer or director change | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 3, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Mar 3, 2026 | 8-K | Regulation FD disclosure | Document |
| Feb 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Feb 12, 2026 | 8-K | Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 7, 1996.
The full analysis
What do Haemonetics's filings show?
The filings are where every one of Haemonetics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.